Navigation Links
Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting
Date:9/12/2007

Over 20 Targanta-Related Posters and Presentations Accepted to Meeting

CAMBRIDGE, Mass., Sept. 12 /PRNewswire/ -- Targanta Therapeutics Corporation today announced that 23 presentations will showcase its lead antibiotic candidate, oritavancin, and its antibiotic drug discovery platform at the upcoming 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place in Chicago, September 17-20, 2007.

Thomas Parr, Ph.D., Chief Scientific Officer of Targanta Therapeutics commented on the meeting: "We are very proud of the body of data being presented on behalf of Targanta at ICAAC this year-a true testament, we believe, to the efforts and expertise of our scientists and collaborators. We continue to be encouraged by the breadth of data supporting the differentiating characteristics of oritavancin and are pleased to be able to present for the first time promising data on our pre-clinical osteomyelitis program."

Throughout the meeting, multiple posters will highlight the in vitro activity of oritavancin, Targanta's investigational antibiotic for the treatment of gram-positive infections, against a wide spectrum of antibiotic susceptible and resistant gram-positive bacteria. In addition, two presentations at ICAAC will highlight Targanta's proprietary drug discovery platform, which utilizes bisphosphonate prodrugs of antibiotics to generate molecules that deliver antibiotics directly to the bone.

The following abstracts have been accepted for poster or slide presentation at ICAAC:

Date Time Number Type Author Title

Monday, 12:00- A-49 Poster Lehoux PK-PD of Oritavancin

Sept. 17 1:00PM CDT (ORI) Against

Streptococcus pneumoniae

(SP) in a Murine-Pneumonia

Infection Model
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Emerging technology companies receive significant funding
3. Genzyme acquistion of Bone Care approved, significant impact forecast
4. BIO 2007: Wisconsin makes its presence felt
5. TDS trades markets to gain Duluth presence
6. West Coast VC Establishes Midwest Presence in Madison
7. Sony Bets Heavy on Wisconsin Digital Entertainment Presence
8. NameProtect releases annual list of top trademarkers
9. Doyle says new contracts saving state more than $16 million annually
10. Department of Commerce offers up to $1 million annually to aid tech entrepreneurs
11. Annual Bioethics Forum to explore genetic testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 CSSi, the leader in ... announced the formation of the company,s Medical and Clinical ... addition of Dr. William E. Gannon, Jr. ... The MCAB, with Dr. Gannon,s ... therapeutic areas and set strategic goals for the advancement ...
(Date:8/19/2014)... /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") ... its Oral Amphotericin B (Oral Amp B) drug ... by ImmuneCarta®, the immune monitoring business unit of ... Oral Amp B in reactivating latent HIV viral ... treatment with antiretroviral therapy. Memory ...
(Date:8/18/2014)... 2014) -- A new therapy developed by researchers ... College of Medicine and Columbia University Medical Center ... interventional cardiovascular disease treatment. , The researchers ... molecular therapy could selectively inhibit blood vessel re-narrowing ... procedure using a balloon catheter to open narrowed ...
(Date:8/18/2014)...   Sterne, Kessler, Goldstein & Fox P.L.L.C. , ... DC , announced today that it has filed ... with the U.S. Patent and Trademark Office (USPTO) on ... Inc. (Nasdaq: BRLI).  These IPR petitions aim to nullify ... Inc. These patents have been asserted against GeneDx in ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3
... Cephalon, Inc. (Nasdaq:,CEPH) today announced that it ... a lawsuit in U.S. District Court in Delaware ... Laboratories,Inc., for infringement of U.S. Patent Nos. 6,200,604 ... Cephalon product FENTORA(R) (fentanyl buccal,tablet) [C-II]. The 6,200,604 ...
... iCAD, Inc. (Nasdaq:,ICAD), an industry-leading provider of Computer-Aided ... Executive Officer, and,Darlene Deptula-Hicks, Executive Vice President and ... corporate update at the Seventh Annual,Needham and Company ... 2008 at 2:00 p.m., (Eastern Daylight Time) at ...
... changes and further organizational ... consolidation ... Paul LaViolette to retire ... that President and Chief Executive,Officer Jim Tobin will be extending his tenure at the Company. The ...
Cached Biology Technology:Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals 2Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals 3iCAD to Present at Seventh Annual Needham and Company Biotechnology and Medical Technology Conference 2Boston Scientific Announces CEO Jim Tobin to Extend Tenure 2Boston Scientific Announces CEO Jim Tobin to Extend Tenure 3Boston Scientific Announces CEO Jim Tobin to Extend Tenure 4Boston Scientific Announces CEO Jim Tobin to Extend Tenure 5
(Date:8/20/2014)... who have suffered concussions ready to return to action? ... high school athletes who head back on the field ... regression in their abilities to simultaneously walk and do ... changes in their balance and/or altered walking speed, was ... 12 had returned to activity in less than a ...
(Date:8/20/2014)... spiciness that is irresistible to some, but intolerable to ... their findings to develop a new drug candidate for ... inflammation or other problems. They reported their progress on ... in ACS, Journal of Medicinal Chemistry . , ... had pegged a compound called capsaicin as the active ...
(Date:8/20/2014)... Your chairs, synthetic rugs and plastic bags could one ... waste rather than petroleum, scientists are now reporting. The ... help the world deal with its agricultural and plastic ... . , Athanassia Athanassiou, Ilker S. Bayer and colleagues ... plastic,s popularity is constantly growing. In 2012, its production ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... Center for Climate Change (BC3) has analysed the expected economic impact ... the Kyoto Protocol for the period 2008-2012 and for the phase ... come out on top in comparison to sectors such as industrial ... Spain have an impact on the economy, in other words, making ...
... (VBI) at Virginia Tech have constructed a mathematical and ... to simulate the cellular and molecular changes underlying chronic ... to explore different interactions of cells in the immune ... in the colon, and identify intervention points to perhaps ...
... HOUSTON -- A novel approach detects genetically abnormal cells in ... abnormalities found in tumor cells and increase in number with ... scientists at The University of Texas MD Anderson Cancer Center ... Lung cancer patients in the study also had many times ...
Cached Biology News:CO2 reduction policies in Spain strengthen the services sector 2Math model of colon inflammation singles out dangerous immune cells 2Math model of colon inflammation singles out dangerous immune cells 3UT MD Anderson study ties abnormal cells in blood to lung cancer 2UT MD Anderson study ties abnormal cells in blood to lung cancer 3
Request Info...
Guinea Pig Complement...
Collected from 8-12 week-old New Zealand or Californian rabbits....
Enables rapid purification of double-stranded DNA fragments = 200 bp, including, for example, PCR reaction products, DNA fragments obtained in restriction enzyme digests, or double-stranded cDNA...
Biology Products: